TD Cowen downgraded shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT – Free Report) from a buy rating to a hold rating in a report published on Wednesday, MarketBeat reports. TD Cowen currently has $4.00 price target on the stock, down from their prior price target of $20.00.
A number of other research firms have also commented on EYPT. Citigroup decreased their price target on Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, August 18th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $5.00 price objective on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, August 18th. Wall Street Zen raised Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 22nd. Cantor Fitzgerald cut Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Monday, August 17th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research note on Monday, August 17th. Four analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Eyepoint Pharmaceuticals has an average rating of “Hold” and an average target price of $25.70.
Check Out Our Latest Analysis on EYPT
Eyepoint Pharmaceuticals Trading Up 0.2%
Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The business had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.45 million. Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. Sell-side analysts predict that Eyepoint Pharmaceuticals will post -3.51 earnings per share for the current fiscal year.
Institutional Trading of Eyepoint Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of EYPT. KBC Group NV bought a new position in Eyepoint Pharmaceuticals in the 1st quarter worth approximately $29,000. California State Teachers Retirement System boosted its position in Eyepoint Pharmaceuticals by 20.6% in the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after buying an additional 794 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Eyepoint Pharmaceuticals in the 3rd quarter valued at $76,000. Persistent Asset Partners Ltd acquired a new stake in shares of Eyepoint Pharmaceuticals in the 4th quarter valued at $98,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Eyepoint Pharmaceuticals by 218.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock worth $82,000 after acquiring an additional 5,967 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.
About Eyepoint Pharmaceuticals
Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.
Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.
Featured Stories
- Five stocks we like better than Eyepoint Pharmaceuticals
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
